Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 9.49TCr 8.65TCr 8.01TCr 7.25TCr 14TCr 8,85100Cr 14TCr 97TCr 38TCr 4,79600Cr 36TCr 35TCr 15,14100Cr P/E 2026 *
16x
P/E 2027 * 15.2x
Enterprise Value 8.77TCr 8TCr 7.4TCr 6.7TCr 13TCr 8,18200Cr 13TCr 89TCr 35TCr 4,43400Cr 33TCr 32TCr 13,99700Cr EV / Sales 2026 *
4.66x
EV / Sales 2027 * 4.08x
Free-Float
72.51%
Yield 2026 *
0.4%
Yield 2027 * 0.42%
1 day-2.35%
1 week-3.76%
Current month-0.49%
1 month+16.77%
3 months+13.96%
6 months+46.64%
Current year+19.62%
1 week 920.24
Extreme 920.24
972.24
1 month 789.69
Extreme 789.69
991.73
Current year 591.52
Extreme 591.52
991.73
1 year 591.52
Extreme 591.52
991.73
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 76 08/01/1988
Date Insider Type Main position Quantity % Market Cap. Importance
04/11/26 Exercice

SVP Controller

11,828 0.0117%
03/11/26 Exercice

Director

22,317 0.0221%
03/11/26 Don

Chief Technology Officer

-1,054 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
-2.35%-3.76%+27.30%+15.07% 9.49TCr
-2.29%-6.00%+31.17%+128.34% 1,23200Cr
-2.04%-4.73%+33.57%+78.34% 66TCr
-0.86%-3.88%+21.24%+105.02% 51TCr
-1.04%-0.67%+30.16%+68.01% 38TCr
-3.61%-9.76%+37.73%+30.53% 34TCr
-3.22%-4.14%+24.75%+51.30% 29TCr
-2.51%-4.26%-1.93%+29.67% 28TCr
-1.14%-6.26%+27.57%+65.35% 24TCr
-1.45%-1.89%+30.94%+120.72% 21TCr
Average -1.79%-2.22%+26.25%+69.23% 42TCr
Weighted average by Cap. -1.42%-2.64%+27.87%+86.17%

Financials

2026 *2027 *
Net sales 1.88TCr 1.72TCr 1.59TCr 1.44TCr 2.7TCr 1,75500Cr 2.83TCr 19TCr 7.6TCr 95TCr 7.06TCr 6.91TCr 3,00200Cr 2.02TCr 1.84TCr 1.7TCr 1.54TCr 2.89TCr 1,88100Cr 3.03TCr 21TCr 8.15TCr 1,01900Cr 7.56TCr 7.41TCr 3,21800Cr
Net income 642.63Cr 585.79Cr 542.25Cr 490.96Cr 921.43Cr 60TCr 965.66Cr 6.54TCr 2.6TCr 32TCr 2.41TCr 2.36TCr 1,02500Cr 655.96Cr 597.94Cr 553.5Cr 501.14Cr 940.54Cr 61TCr 985.69Cr 6.68TCr 2.65TCr 33TCr 2.46TCr 2.41TCr 1,04700Cr
Net Debt -716.8Cr -653.4Cr -604.83Cr -547.62Cr -1.03TCr -67TCr -1.08TCr -7.3TCr -2.9TCr -36TCr -2.69TCr -2.63TCr -1,14400Cr -1.25TCr -1.14TCr -1.06TCr -956.3Cr -1.79TCr -1,16800Cr -1.88TCr -13TCr -5.06TCr -63TCr -4.7TCr -4.6TCr -1,99700Cr
Projected Income Statement - Annual - Regeneron Pharmaceuticals, Inc.
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
19/26/19 $923.34 -2.35% 7,18,039
18/26/18 $945.53 -1.28% 7,05,406
17/26/17 $957.76 +0.56% 9,33,408
16/26/16 $952.40 -0.32% 7,00,861
13/26/13 $955.47 +0.45% 11,65,717
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Regeneron Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
923.34USD
Average target price
991.00USD
Spread / Average Target
+7.33%
  1. Stock Market
  2. Stocks
  3. REGN Stock